Pozen’s drug combination technology has received patent protection in Europe, the company said Tuesday.

The patent covers MT-400 under which Pozen combines triptans, a family of drugs designed to treat migraine headaches, and a non-steroidal anti-inflammatory drug.

Pozen is developing a combination drug called Trezima along with GlaxsoSmithKline.

The patent covers 18 European countries. Pozen is seeking patent coverage in Canada and Japan. It has already received protection in the US and Australia.

Pozen: www.Pozen.com